Unigestion Holding SA lowered its stake in Eli Lilly And Co (NYSE:LLY) by 11.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 668,553 shares of the company’s stock after selling 84,739 shares during the period. Eli Lilly And Co makes up approximately 1.5% of Unigestion Holding SA’s holdings, making the stock its 10th biggest position. Unigestion Holding SA owned about 0.06% of Eli Lilly And Co worth $71,742,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in LLY. Principal Financial Group Inc. lifted its position in shares of Eli Lilly And Co by 8.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,807,947 shares of the company’s stock worth $139,881,000 after purchasing an additional 138,746 shares during the last quarter. Trust Co. of Vermont increased its stake in Eli Lilly And Co by 10.1% during the second quarter. Trust Co. of Vermont now owns 9,708 shares of the company’s stock valued at $828,000 after acquiring an additional 893 shares during the period. Xact Kapitalforvaltning AB increased its stake in Eli Lilly And Co by 3.9% during the second quarter. Xact Kapitalforvaltning AB now owns 205,241 shares of the company’s stock valued at $17,513,000 after acquiring an additional 7,697 shares during the period. First Citizens Bank & Trust Co. bought a new position in Eli Lilly And Co during the second quarter valued at about $296,000. Finally, Pennsylvania Trust Co increased its stake in Eli Lilly And Co by 9.2% during the second quarter. Pennsylvania Trust Co now owns 12,995 shares of the company’s stock valued at $1,109,000 after acquiring an additional 1,100 shares during the period. 76.17% of the stock is owned by institutional investors.
In other news, insider Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total value of $63,342.00. Following the sale, the insider now directly owns 3,530 shares in the company, valued at approximately $372,662.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares in the company, valued at $44,081,058. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,881,684 shares of company stock worth $133,274,076. Corporate insiders own 0.11% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Wednesday, July 18th. Bank of America boosted their price target on Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a research note on Wednesday, July 25th. TheStreet lowered Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. Finally, BMO Capital Markets boosted their price target on Eli Lilly And Co from $80.00 to $90.00 and gave the company a “market perform” rating in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $111.19.
LLY stock opened at $112.21 on Friday. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61. The company has a market capitalization of $116.23 billion, a PE ratio of 26.22, a P/E/G ratio of 1.75 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.09 and a current ratio of 1.91.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period in the prior year, the company posted $1.05 EPS. The company’s revenue was up 7.1% compared to the same quarter last year. Analysts forecast that Eli Lilly And Co will post 5.57 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.01%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/11/10/unigestion-holding-sa-has-71-74-million-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: How is Preferred Stock Different from Common Stock?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.